Preparatory neuronal activity in ALM is decreased, but remains significant in quiet trials devoid of movements. by Vahid Esmaeili (12700352)

Changes in the 12 gastrointestinal symptoms based on the FSSG scores from 2010 to 2019 among generally healthy individuals in Japan. by Nobutake Yamamichi (381131)

Decrease of admissions and lead diagnoses. by Petr Fulin (8380320)

Subjects:

Top 20 genes with significantly decreased abundance in Aco^R cells. by Pieter C. Steketee (10024552)

Subjects:

Data_Sheet_1_Intercropping changed the soil microbial community composition but no significant effect on alpha diversity.docx by Jiaying Liu (2371606)

“…At the phylum level, intercropping significantly increased the relative abundance of four dominant phyla, i.e., Patescibacteria, Proteobacteria, Patescibacteria and Deinococcus-Thermus. …”

Significantly changed USSs in the sf3b1 mutants. by Bei Zhang (428038)

Interaction of significantly changed genes and their linked pathways. by Mohamad Ammar Ayass (13775290)

Transcripts with increased translation efficiency during GSC to DGC transition have a significant loss in m6A methylation. by John P. Zepecki (10271291)

“…C) Percent composition of top 30% transcripts with most significant change in TE based on m6A status in individual samples (gain/unchanged/loss). …”

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

Subjects: